Details

Autor(en) / Beteiligte

• Borowiec, Anna
• Ozdowska, Patrycja
• Rosinska, Magdalena
• Jagiello-Gruszfeld, Agnieszka
• Jasek, Slawomir
• Waniewska, Joanna
• Kotowicz, Beata
• Kosela-Paterczyk, Hanna
• Lampka, Elzbieta
• Makowka, Agata
• Fuksiewicz, Malgorzata
• Chojnacka, Magdalena
• Zebrowska, Agnieszka
• Gepner, Katarzyna
• Kapala, Aleksandra
• Cieszanowski, Andrzej
• Nowecki, Zbigniew
• Walewski, Jan

Titel

Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction

Ist Teil von

• PloS one, 2023-08, Vol.18 (8), p.e0288146

Ort / Verlag

Public Library of Science

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Cardiological complications of oncological treatment, including the most serious one, heart failure, constitute a significant and still unsolved clinical problem. A history of dyslipidemia and complications of atherosclerosis, including coronary artery disease, are established risk factors for cardiotoxicity in cancer patients. In recent years, a protective effect of statin treatment on the development of heart failure in cancer patients has been observed. This protocol describes a study aiming to assess the prognostic value of coronary atherosclerosis burden and the CAC score on the onset of cardiac dysfunction associated with cancer therapy. ANTEC (Atherosclerosis iN chemoTherapy-rElated Cardiotoxicity) is a single-site, prospective, observational study to evaluate the influence of the coronary atherosclerosis and CAC score assessed by computed tomography on the development of left ventricular systolic dysfunction in cancer patients with at least moderate cardiotoxicity risk. A group of 80 patients diagnosed with cancer prior to high-dose anthracycline chemotherapy (doxorubicin [greater than or equal to] 240 mg / m2 body weight or epirubicin [greater than or equal to] 600 mg / m2 body weight), without a history of heart failure and coronary artery disease, will be included in the study. Patient follow-up is planned for 12 months. In all patients, coronary computed tomographic angiography (CCTA) will be performed once at the beginning of the study. The primary endpoint is the onset of cancer therapy-related cardiovascular toxicity, defined as mild, moderate, severe and very severe according to ESC 2022 Cardio-oncology guidelines. During follow up, echocardiography with GLS assessment will be performed every three months. Additionally, new biomarkers of atherosclerosis (IL-6, MPO, TNF-alpha) will be measured every 6 months. The study registration identifier on clinicaltrials.gov is NCT05118178.